Rate of hepatitis C reinfection after successful direct-acting antivirals treatment among people who inject drugs in Spain: the LIVERate study
Por:
Chacón, F, Morano, L, Navarro, J, Granados, R, Llibre, JM, Ryan, P, Aldámiz-Echevarria, T, Carbonero, LM, Puigvehi, M, Clotet-Codina, I, Sanchez-Vega, N, Vacas, E, Rincón, O, Berenguer, J, Crespo, J and Roncero, C
Publicada:
14 nov 2024
Ahead of Print:
14 nov 2024
Resumen:
BackgroundHepatitis C virus (HCV) reinfection following successful treatment threatens the achievement of HCV elimination. The primary aim of this study is to assess reinfection rate three years after sustained virologic response (SVR) in people who inject drugs (PWID) that are on opioid agonist treatment (OAT) who underwent anti-HCV treatment with interferon-free regimens.MethodsObservational, non-interventional, prospective, descriptive study carried out in Spanish tertiary public hospitals between 2017 and 2022. Participants comprised 186 adult HCV infected individuals, 85.5% males with a mean age (Standard Deviation, SD) of 50.1 (5.9). All were enrolled in an OAT program at baseline and had attained SVR 12 weeks after therapy completion with an interferon-free treatment. Baseline data were abstracted from medical chart information collected through the routine clinical practice.ResultsThe overall rate of HCV reinfection three years after SVR12 among PWID was 1.2 new cases per 100 person-years of follow-up at a median of 15.9 months. In the subgroup analyses, those with injection drug practice and without a stable housing had higher reinfection rates.ConclusionAlthough PWID in OAT present a low rate of reinfection by HCV after successful treatment, a closer monitoring in the first year and strengthening inter-consultations with services responsible for monitoring addiction in these patients will be crucial to reduce risky behaviors avoiding HCV reinfection.
Filiaciones:
Chacón, F:
Merck Sharp & Dohme Ltd, Madrid, Spain
Morano, L:
Alvaro Cunqueiro Univ Hosp, Vigo, Spain
Navarro, J:
Vall dHebron Univ Hosp, Barcelona, Spain
Granados, R:
Doctor Negrin Univ Hosp Gran Canaria, Las Palmas Gran Canaria, Spain
:
Germans Trias i Pujol Hosp, Badalona, Spain
Ryan, P:
Infanta Leonor Univ Hosp, Madrid, Spain
Ctr Invest Biomed RED Enfermedades Infecciosas CIB, Madrid, Spain
Univ Complutense Madrid, Madrid, Spain
Inst Invest Sanitaria Gregorio Maranon IiSGM, Madrid, Spain
Aldámiz-Echevarria, T:
Gregorio Maranon Univ Hosp, Madrid, Spain
Carbonero, LM:
La Paz Univ Hosp, Madrid, Spain
Puigvehi, M:
Del Mar Hosp, Barcelona, Spain
Clotet-Codina, I:
Merck Sharp & Dohme Ltd, Madrid, Spain
Sanchez-Vega, N:
Merck Sharp & Dohme Ltd, Madrid, Spain
Vacas, E:
Merck Sharp & Dohme Ltd, Madrid, Spain
Rincón, O:
Merck Sharp & Dohme Ltd, Madrid, Spain
Berenguer, J:
Inst Invest Sanitaria Gregorio Maranon IiSGM, Madrid, Spain
Crespo, J:
Marques Valdecilla Univ Hosp, Santander, Spain
Roncero, C:
European Univ Miguel de Cervantes, Hlth Sci Fac, Valladolid, Spain
Green Accepted, gold
|